|
|
|
|
As drug development becomes increasingly expensive and complex, pharma companies are relying on CDMOs to maximize efficiencies. This allows firms to reserve resources for business growth while CDMO partners with extensive experience and expertise can focus on development and manufacturing. Examine the opportunities and challenges of end-to-end arrangements.
|
|
|
|
|
Optimizing drug development, manufacturing, and supply is critical if companies are to translate innovation into therapeutic and commercial gains. However, growing complexity and risks in the industry are impacting outsourcing models. Companies must consider how best they can structure and manage CDMO partnerships to weather routine uncertainty and disruption.
|
|
|
|
|
Impurities in drug products can arise at various time points during the manufacturing or storage processes. Without swift identification to assess potential risk, they can stall critical clinical timelines or cause a product recall. Understand how to manage impurities in drug development with swift isolation, synthesis, and analysis.
|
|
|
|
|
Drug producers face increasing stringency from regulatory authorities to substantiate the purity of drug products. Qualified reference standards play a critical role in providing validated benchmarks to satisfy regulatory requirements. An experienced CDMO can connect the value of investing in qualified reference standards to the impact on final product quality.
|
|
|
|
|
|
|
Fluid and transparent communication is an essential element of a successful CDMO relationship. Hear an industry expert share his perspective from both the pharmaceutical and CDMO sides of the table on why partnering with a collaborative CDMO can make a significant impact on a program’s success.
|
|
|
